Evidence map›Paper›PMID 35527823›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2022

Preparation, characterization,

Mothanna Sadiq Al-Qubaisi, Ashwaq Shakir Al-Abboodi, Fatah H Alhassan, Samer Hussein-Al-Ali, Moayad Husein Flaifel, Eltayeb E M Eid, Hussah Abdullah Alshwyeh, Mohd Zobir Hussein, Sulaiman Mohammed Alnasser, Mohammed Ibrahim Saeed and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular & cellular oncology · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

Mothanna Sadiq Al-QubaisiInstitute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Ashwaq Shakir Al-AbboodiBasic Science Branch, Faculty of Dentistry, University of Al-Qadisiyah, Al-Diwaniyah, Iraq.
Fatah H AlhassanDepartment of Applied Chemistry and Technology, College of Science and Arts, Alkamel University of Jeddah, Jeddah 21589, Saudi Arabia.
Samer Hussein-Al-AliFaculty of Pharmacy, Isra University, Amman 11622, Jordan.
Moayad Husein FlaifelDepartment of Physics, College of Science, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Eltayeb E M EidDepartment of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.
Hussah Abdullah AlshwyehBasic & Applied Scientific Research Center, College of Science, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Mohd Zobir HusseinDepartment of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Sulaiman Mohammed AlnasserDepartment of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.
Mohammed Ibrahim SaeedFaculty of Medical Laboratory Sciences, National Ribat University, Khartoum 11111, Sudan.
Abdullah RasedeeInstitute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Wisam Nabeel IbrahimDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Universiti Putra Malaysia · MYImam Abdulrahman Bin Faisal University · SAQassim University · SAIsra University · JOJeddah University · SANational Ribat University · SDQatar University · QAUniversity of Al-Qadisiyah · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we formulated Thymoquinone-loaded nanocomposites (TQ-NCs) using high-pressure homogenizer without sodium tripolyphosphate. The TQ-NCs were characterized and their anti-inflammatory determined by the response of the LPS-stimulated macrophage RAW 264.7 cells in the production of nitric oxide, prostaglandin E2, tumor necrosis factor-α, interleukin-6, and interleukin-1β. The physicochemical properties of TQ-NC were determined using different machines. TQ was fully incorporated in the highly thermal stable nanoparticles. The nanoparticles showed rapid release of TQ in the acidic medium of the gastric juice. In medium of pH 6.8, TQ-NC exhibited sustained release of TQ over a period of 100 h. The results suggest that TQ-NC nanoparticles have potential application as parenterally administered therapeutic compound. TQ-NC effectively reduce production of inflammatory cytokines by the LPS-stimulated RAW 264.7 cells, indicating that they have anti-inflammatory properties. In conclusion, TQ-NC nanoparticles have the characteristics of efficient carrier for TQ and an effective anti-inflammatory therapeutic compound.

Indexed as

Drug releaseHigh-pressure homogenizerInflammatory mediatorsNanocompositeRAW 264.7 cellsThymoquinone

Identifiers

PMID35527823
PMCPMC9068746
OpenAlexW4210921529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.